Azura Ophthalmics
Shimon Nahum has served as Senior Manager Formulation and CMC of Azura Ophthalmics since January 2018. Shimon has 10 years of formulation development experience across a variety of dosage forms in the pharmaceutical and cosmetic industries. Prior to joining Azura Ophthalmics, Shimon was Project Coordinator at Teva Pharmaceuticals within the specialty R&D unit in charge of the development of New Chemical Entities and Drug-Device combinations. While at Teva, Shimon also worked across the generics unit responsible for the development of nasal products. He also spent four years at sister companies Tree of Life Pharma and Panaxia Pharmaceuticals as Formulation Team Leader, developing over the counter drug products, dermal filers and cannabis-based treatments. Shimon was the key developer in formulation and analytical method development enabling the business to establish spin-offs including Luminera Ltd, a manufacturer of injectable medical devices in the medical aesthetic field, and Panaxia Medical Cannabis Ltd.
This person is not in any offices
Azura Ophthalmics
1 followers
Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the United States. The company is developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction (MGD), the leading cause of Dry Eye Disease (DED). By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking.